GoodRx Holdings (GDRX) shares have slipped about 27% over the past month, drawing investor attention to recent performance trends. The company’s ongoing path sparks questions about how current ...
GoodRx Holdings (GDRX) shares saw a dip today, closing down about 11%. While there was no material news event driving the move, it comes after a recent streak of strong gains over the past week. See ...
GoodRx Holdings Inc. reported its second-quarter earnings for 2025, falling short of market expectations. The company announced earnings per share (EPS) of $0.09, slightly below the forecast of $0.10, ...
“GoodRx is scaling a consumer-first model for affordable GLP-1 treatment,” said Wendy Barnes, President and CEO of GoodRx. “We’re committed to connecting consumers with FDA-approved GLP-1 medications ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make FDA-approved GLP-1 medications more ...
GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...
GoodRx announced that eligible self-paying patients can now access all strengths of Ozempic and Wegovy pens for $499 per month through its platform, effective immediately. The collaboration marks the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback